Remote monitoring using donor-derived, cell-free DNA after kidney transplantation during the coronavirus disease 2019 pandemic
Background : Donor-derived, cell-free DNA (dd-cfDNA) level correlates with allograft injury with clinical validity and utility for quiescence and active acute rejection (AR) in kidney transplant recipients. We analyzed trends in dd-cfDNA level immediately preceding and during the coronavirus disease 2019 (COVID-19) pandemic with implemented “shelter in place” and a tele-health strategy with remote home phlebotomy to limit COVID-19 exposure. Methods : During COVID-19 in the United States (US), we surveyed weekly (January 6, 2020-May 25, 2020) metrics for dd-cfDNA corresponding to both a low risk for active rejection (dd-cfDNA < 0.5%) and cohorts with indeterminate levels of 0.5% to 1.0% and < 1.0%. During the study timeframe, over 11,000 patient samples (67%) from 150 kidney transplantation centers were transitioned from standard facility-based to remote phlebotomy. Results : The proportion of dd-cfDNA samples, analyzed in 21 weekly aggregated cohorts by risk-stratification category, was unchanged during the COVID-19 escalation in the US. Linearized slopes for numbers of samples corresponding to indeterminate risk for AR cohorts of < 1.0% and 0.5% to 1.0% were -0.31 and -0.12, respectively; indicating that prevalence of these “at risk for AR cohorts” decreased during remote surveillance. Approximately 73% of samples corresponded to low risk of AR (dd-cfDNA < 0.5%), while an additional 15% of samples had dd-cfDNA level ≤ 1.0%. Conclusion : The combination of remote home phlebotomy including dd-cfDNA analysis and a tele-health program offer a new paradigm that may substantially improve patient compliance and assuage anxiety regarding the state of kidney allograft health during the COVID-19 pandemic. Further prospective multi-center studies with robust outcomes data are warranted..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Kidney Research and Clinical Practice - 39(2020), 4, Seite 495-500 |
| Sprache: |
Englisch ; Koreanisch |
|---|
| Beteiligte Personen: |
Steven R. Potter [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Biomarker |
|---|
| doi: |
10.23876/j.krcp.20.107 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ061060569 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ061060569 | ||
| 003 | DE-627 | ||
| 005 | 20230503095721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.23876/j.krcp.20.107 |2 doi | |
| 035 | |a (DE-627)DOAJ061060569 | ||
| 035 | |a (DE-599)DOAJ55f29bd10ec047b7b8a176c48178dd55 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a kor | ||
| 050 | 0 | |a RC31-1245 | |
| 050 | 0 | |a RC581-951 | |
| 100 | 0 | |a Steven R. Potter |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Remote monitoring using donor-derived, cell-free DNA after kidney transplantation during the coronavirus disease 2019 pandemic |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background : Donor-derived, cell-free DNA (dd-cfDNA) level correlates with allograft injury with clinical validity and utility for quiescence and active acute rejection (AR) in kidney transplant recipients. We analyzed trends in dd-cfDNA level immediately preceding and during the coronavirus disease 2019 (COVID-19) pandemic with implemented “shelter in place” and a tele-health strategy with remote home phlebotomy to limit COVID-19 exposure. Methods : During COVID-19 in the United States (US), we surveyed weekly (January 6, 2020-May 25, 2020) metrics for dd-cfDNA corresponding to both a low risk for active rejection (dd-cfDNA < 0.5%) and cohorts with indeterminate levels of 0.5% to 1.0% and < 1.0%. During the study timeframe, over 11,000 patient samples (67%) from 150 kidney transplantation centers were transitioned from standard facility-based to remote phlebotomy. Results : The proportion of dd-cfDNA samples, analyzed in 21 weekly aggregated cohorts by risk-stratification category, was unchanged during the COVID-19 escalation in the US. Linearized slopes for numbers of samples corresponding to indeterminate risk for AR cohorts of < 1.0% and 0.5% to 1.0% were -0.31 and -0.12, respectively; indicating that prevalence of these “at risk for AR cohorts” decreased during remote surveillance. Approximately 73% of samples corresponded to low risk of AR (dd-cfDNA < 0.5%), while an additional 15% of samples had dd-cfDNA level ≤ 1.0%. Conclusion : The combination of remote home phlebotomy including dd-cfDNA analysis and a tele-health program offer a new paradigm that may substantially improve patient compliance and assuage anxiety regarding the state of kidney allograft health during the COVID-19 pandemic. Further prospective multi-center studies with robust outcomes data are warranted. | ||
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a cell-free nucleic acids | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a donor-derived dna | |
| 650 | 4 | |a kidney transplantation | |
| 653 | 0 | |a Internal medicine | |
| 653 | 0 | |a Specialties of internal medicine | |
| 700 | 0 | |a Randall Hinojosa |e verfasserin |4 aut | |
| 700 | 0 | |a Cliff D. Miles |e verfasserin |4 aut | |
| 700 | 0 | |a Dan O'Brien |e verfasserin |4 aut | |
| 700 | 0 | |a David J. Ross |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Kidney Research and Clinical Practice |d The Korean Society of Nephrology, 2018 |g 39(2020), 4, Seite 495-500 |w (DE-627)DOAJ000113328 |x 22119140 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2020 |g number:4 |g pages:495-500 |
| 856 | 4 | 0 | |u https://doi.org/10.23876/j.krcp.20.107 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/55f29bd10ec047b7b8a176c48178dd55 |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.23876/j.krcp.20.107 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2211-9132 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2020 |e 4 |h 495-500 | ||